TOP TEN perturbations for 1553486_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553486_a_at
Selected probe(set): 1553486_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553486_a_at (1553486_a_at) across 6673 perturbations tested by GENEVESTIGATOR:

gastric cancer study 7 (mixed Signet ring cell adenocarcinoma) / gastric cancer study 7 (adenocarcinoma, intestinal type)

Relative Expression (log2-ratio):2.1992035
Number of Samples:3 / 21
Experimental gastric cancer study 7 (mixed Signet ring cell adenocarcinoma)
Primary tumor tissue sample obtained from the gastrointestinal tract of patients with mixed Signet ring cell adenocarcinoma.
Control gastric cancer study 7 (adenocarcinoma, intestinal type)
Primary tumor tissue sample obtained from the gastrointestinal tract of patients with adenocarcinoma (intestinal type).

gastric cancer study 7 (mixed Signet ring cell adenocarcinoma) / gastric cancer study 7 (carcinoma, diffuse type)

Relative Expression (log2-ratio):2.0770607
Number of Samples:3 / 29
Experimental gastric cancer study 7 (mixed Signet ring cell adenocarcinoma)
Primary tumor tissue sample obtained from the gastrointestinal tract of patients with mixed Signet ring cell adenocarcinoma.
Control gastric cancer study 7 (carcinoma, diffuse type)
Primary tumor tissue sample obtained from the gastrointestinal tract of patients with carcinoma (diffuse type).

colorectal cancer study 33 (adenocarcinoma; asc. colon) / normal ascending colon tissue

Relative Expression (log2-ratio):1.8817062
Number of Samples:3 / 3
Experimental colorectal cancer study 33 (adenocarcinoma; asc. colon)
Primary tumor samples derived from the ascending colon of patients with adenocarcinoma.
Control normal ascending colon tissue
Normal ascending colon tissue samples.

gastric cancer study 7 (neoplasm, malignant) / gastric cancer study 7 (mixed Signet ring cell adenocarcinoma)

Relative Expression (log2-ratio):-1.8718557
Number of Samples:37 / 3
Experimental gastric cancer study 7 (neoplasm, malignant)
Primary tumor tissue sample obtained from the gastrointestinal tract of patients with malignant neoplasm (unspecified type).
Control gastric cancer study 7 (mixed Signet ring cell adenocarcinoma)
Primary tumor tissue sample obtained from the gastrointestinal tract of patients with mixed Signet ring cell adenocarcinoma.

gastric cancer study 7 (mixed Signet ring cell adenocarcinoma) / gastric cancer study 7 (adenocarcinoma, NOS)

Relative Expression (log2-ratio):1.7155561
Number of Samples:3 / 84
Experimental gastric cancer study 7 (mixed Signet ring cell adenocarcinoma)
Primary tumor tissue sample obtained from the gastrointestinal tract of patients with mixed Signet ring cell adenocarcinoma.
Control gastric cancer study 7 (adenocarcinoma, NOS)
Primary tumor tissue sample obtained from the gastrointestinal tract of patients with adenocarcinoma, (NOS).

colorectal cancer study 13 (tvvad) / colorectal cancer study 13 (hypp. pol.)

Relative Expression (log2-ratio):1.4955387
Number of Samples:3 / 11
Experimental colorectal cancer study 13 (tvvad)
Colon biopsies derived from patients with low grade tubulovillous/villous adenoma.
Control colorectal cancer study 13 (hypp. pol.)
Colon biopsies derived from patients with hyperplastic polyps.

expO breast cancer study 1 (lobular carcinoma, NOS; primary) / expO breast cancer study 1 (lobular carcinoma, NOS; metastatic)

Relative Expression (log2-ratio):-1.3281908
Number of Samples:39 / 4
Experimental expO breast cancer study 1 (lobular carcinoma, NOS; primary)
Primary tumor tissue samples obtained from the breast of patients with lobular carcinoma (NOS).
Control expO breast cancer study 1 (lobular carcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary lobular carcinoma (NOS) of the breast.

Crohn's disease study 6 (colon only; under therapy) / normal colon tissue

Relative Expression (log2-ratio):1.0347996
Number of Samples:4 / 11
Experimental Crohn's disease study 6 (colon only; under therapy)
Colon biopsies derived from pediatric patients diagnosed with colon-only Crohn's disease (any colonic location between cecum and rectum with no small bowel disease) enrolled during therapy. Patients were receiving medications for the treatment of inflammatory bowel disease at the time the biopsy was taken. Patients may also have concomitant upper gastrointestinal tract and/or perianal disease.
Control normal colon tissue
Colon biopsies derived from pediatric healthy controls.

colorectal cancer study 28 (primary; SD) / colorectal cancer study 28 (primary; PD)

Relative Expression (log2-ratio):-1.0020328
Number of Samples:15 / 10
Experimental colorectal cancer study 28 (primary; SD)
Colorectal tissue samples derived from the primary site of patients with unresectable colorectal carcinoma. Tumor sample was taken before mFOLFOX6 therapy (85 mgm2 OHP, 200 mgm2 LV, and 400 mgm2 5-FU bolus on day 1, and 2400 mgm2 5-FU as a 46-h continuous infusion starting on day 1, which is repeated every 2 weeks). After 4 cycles of mFOLFOX6 therapy treatment success was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) evaluation system. Patients in this group were classified as stable disease (SD, neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD).
Control colorectal cancer study 28 (primary; PD)
Colorectal tissue samples derived from the primary site of patients with unresectable colorectal carcinoma. Tumor sample was taken before mFOLFOX6 therapy (85 mgm2 OHP, 200 mgm2 LV, and 400 mgm2 5-FU bolus on day 1, and 2400 mgm2 5-FU as a 46-h continuous infusion starting on day 1, which is repeated every 2 weeks). After 4 cycles of mFOLFOX6 therapy treatment success was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) evaluation system. Patients in this group were classified as progressive disease (PD, at least a 10% increase in the sum of the longest diameter of target lesions).

colorectal adenoma study 7 (colonic crypt) / normal colonic crypt epithelial cell sample

Relative Expression (log2-ratio):0.94650793
Number of Samples:5 / 5
Experimental colorectal adenoma study 7 (colonic crypt)
Colonic crypt epithelial cell samples obtained by laser capture microdissection (LCM) from patients with colorectal adenoma.
Control normal colonic crypt epithelial cell sample
Histopathological normal colonic crypt epithelial cells obtained by laser capture microdissection (LCM) from the distant normal colon of patients with colorectal cancer.